Semaglutide(sem a gloo' tide)

Ozempic is FDA-approved for type 2 diabetes, not weight management. Clinicians sometimes prescribe Ozempic off-label for weight management when Wegovy is unavailable or denied by insurance, but this approach has complications: lower maximum dose (2.0 mg vs Wegovy 2.4 mg), insurance often denies coverage when used off-label, and the manufacturer Savings Card is not designed for off-label use. Patients seeking weight management benefit typically do better requesting Wegovy specifically.

From the Ozempic editorial review.

Same active ingredient (semaglutide), but different products. Ozempic is FDA-approved for type 2 diabetes at 0.25–2.0 mg weekly. Wegovy is FDA-approved for chronic weight management at higher 2.4 mg weekly. Different pen device, different labeling, different insurance coverage. The molecule is identical; the dose, indication, and pricing differ.

From the Ozempic editorial review.

In SUSTAIN-6 and SUSTAIN-7 trials, diabetic patients lost ~3–6% body weight on average over 56 weeks at the 0.5–1.0 mg doses. The 2.0 mg dose (approved in 2022) produces somewhat more weight loss, closer to ~7–9% body weight reduction. Weight loss on Ozempic is generally less than Wegovy because the maximum approved dose is lower.

From the Ozempic editorial review.

Yes — that's its primary FDA-approved use. Trial data shows HbA1c reduction of ~1.0–1.5 percentage points from baseline at 30 weeks, depending on dose. The cardiovascular benefit (SUSTAIN-6 trial) extends to a documented reduction in major adverse cardiovascular events (MACE) in patients with T2DM and established cardiovascular disease.

From the Ozempic editorial review.

For type 2 diabetes, Ozempic is typically considered a chronic medication — like statins or antihypertensives. Discontinuation often leads to HbA1c rising and weight regain. Some patients in sustained remission with significant lifestyle changes may successfully taper or discontinue, but this is uncommon and should be done with close clinical monitoring.

From the Ozempic editorial review.

The FDA semaglutide shortage was declared resolved in late 2024. As of 2026, brand-name Ozempic supply is generally adequate. Compounded semaglutide alternatives that filled the shortage gap are being wound down by FDA enforcement; routine 503A compounding for semaglutide may continue in limited individualized cases but not at scale. Stick with brand-name Ozempic from authorized pharmacies for reliable supply.

From the Ozempic editorial review.

Same active ingredient (semaglutide), different brand and different FDA-approved indications. Wegovy is FDA-approved for chronic weight management at a maintenance dose of 2.4 mg weekly. Ozempic is FDA-approved for type 2 diabetes at 0.25–2.0 mg weekly. The molecules are identical; the dosing and labeled use differ. Clinicians sometimes prescribe Ozempic off-label for weight management, though insurance coverage and cost differ markedly.

From the Wegovy editorial review.

Weight loss is gradual and titration-dependent. Typical pattern: 1–3% body weight reduction during the first 4 weeks at the 0.25 mg starting dose, then progressively more as the dose escalates. STEP-1 trial participants reached ~10% body weight reduction by week 28 and ~15% by week 68. Individual response varies — about 13% of trial participants had ≤5% weight loss, and about 32% reached ≥20% reduction.

From the Wegovy editorial review.